Correlation Between Zenas BioPharma, and Dogwood Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Zenas BioPharma, and Dogwood Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zenas BioPharma, and Dogwood Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zenas BioPharma, Common and Dogwood Therapeutics,, you can compare the effects of market volatilities on Zenas BioPharma, and Dogwood Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zenas BioPharma, with a short position of Dogwood Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zenas BioPharma, and Dogwood Therapeutics,.

Diversification Opportunities for Zenas BioPharma, and Dogwood Therapeutics,

-0.54

Correlation Coefficient

Zenas BioPharma,  Dogwood Therapeutics,

Excellent diversification

The 3 months correlation between Zenas and Dogwood is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Zenas BioPharma, Common and Dogwood Therapeutics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dogwood Therapeutics, and Zenas BioPharma, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zenas BioPharma, Common are associated (or correlated) with Dogwood Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dogwood Therapeutics, has no effect on the direction of Zenas BioPharma, i.e., Zenas BioPharma, and Dogwood Therapeutics, go up and down completely randomly.

Pair Corralation between Zenas BioPharma, and Dogwood Therapeutics,

Given the investment horizon of 90 days Zenas BioPharma, Common is expected to under-perform the Dogwood Therapeutics,. But the etf apears to be less risky and, when comparing its historical volatility, Zenas BioPharma, Common is 8.3 times less risky than Dogwood Therapeutics,. The etf trades about -0.08 of its potential returns per unit of risk. The Dogwood Therapeutics, is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  252.00  in Dogwood Therapeutics, on December 4, 2024 and sell it today you would earn a total of  177.00  from holding Dogwood Therapeutics, or generate 70.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Zenas BioPharma, Common  vs.  Dogwood Therapeutics,

Zenas BioPharma, Common

Risk-Adjusted Performance

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Dogwood Therapeutics,

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Dogwood Therapeutics, are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Dogwood Therapeutics, showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Zenas BioPharma, and Dogwood Therapeutics,

The main advantage of trading using opposite Zenas BioPharma, and Dogwood Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zenas BioPharma, position performs unexpectedly, Dogwood Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dogwood Therapeutics, will offset losses from the drop in Dogwood Therapeutics,'s long position.

The idea behind Zenas BioPharma, Common and Dogwood Therapeutics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.